Akbulut, SamiBagci, NazlicanAkyuz, MusapGarzali, Ibrahim UmarSaritas, HasanTamer, MuratInce, Volkan2024-08-042024-08-0420230041-13451873-2623https://doi.org/10.1016/j.transproceed.2023.01.038https://hdl.handle.net/11616/101326Background and Aim. Many clinical studies have shown that the COVID-19 case fatality rate is higher in older patients, those with comorbidities, those with immunosuppressive conditions, and those who stay in the intensive care unit. This study aims to evaluate the clinical outcomes of 66 liver transplant (LT) patients with primary liver cancer who were exposed to COVID-19 infection.Methods. Demographic and clinical data of 66 patients with primary liver cancer (hepatocellu-lar carcinoma = 64, hepatoblastoma = 1, cholangiocarcinoma = 1) who underwent LT in our institute and were exposed to COVID-19 infection between March 2020 and November 2021 were analyzed in this cross-sectional study. The following data of the patients were recorded: age, sex, body mass index (kg/m2), blood group, underlying primary liver disease, smoking, tumor characteristics, post-transplant immunosuppressive agents, COVID-19 symptoms, hospi-talization, intensive care unit stay, intubation, and other clinical features. Results. There were 55 (83.3%) male and 11 (16.7%) female patients, with a median age of 58 years. Sixty-four patients were exposed to COVID-19 only once, whereas the remaining 2 patients were exposed 2 and 4 times, respectively. After exposure to COVID-19, it was deter-mined that 37 patients used antiviral drugs, 25 were hospitalized, 9 were followed in the inten-sive care unit, and 3 were intubated. One intubated patient was under hospital follow-up because of biliary complications before exposure to COVID-19, and this patient died from sepsis. Conclusion. The low mortality rate of LT patients with primary liver cancer exposed to COVID-19 infection can be attributed to background immunosuppression that prevents cytokine storm. However, it is appropriate to support this study with multicenter studies to make strong comments on this issue.eninfo:eu-repo/semantics/openAccessSars-Cov-2Article555122612303713776210.1016/j.transproceed.2023.01.0382-s2.0-85154029934Q3WOS:001035795600001Q4